



AM Notice: AM 2014/01 Date of Issue: 29/04/2014

# **Analysis Method Notice**

# Delivery of the Cancer 31 Day Waiting Times Target Patients Newly Diagnosed with Cancer, not via the urgency cancer route, that started definitive treatment within 31 days of diagnosis

An accredited Analysis Method describes a method that has been agreed for use in the production of published national outcome indicators, performance measures and/or currencies

Analysis Methods are developed and / or agreed by the Analysis Methodologies Group. They are accredited by the Welsh Information Standards Board. For further details about the group, including Terms of Reference and membership, please visit the following website:

http://howis.wales.nhs.uk/sites3/page.cfm?orgid=742&pid=56696

WISB Reference: IGRN Ref. 2007/019

Please address enquiries about this Analysis Method the NHS Wales Informatics Service Data Standards Team.

E-mail: data.standards@wales.nhs.uk / Tel: 029 2050 2539

WISB Appraisal Assessment	Accredited This Analysis Method has been appraised by WISB and is felt to be fit for purpose in that it:  • Meets the business requirement; • Is reproducible by organisations, where appropriate.
Status of Data Standards Assurance	WISB Reviewed The data used in this Analysis Method are based on data item standards that have been through the Information Standards Assurance Process.
WISB Outcome(s)	Outcome

AM 2014/01 Page 1 of 5

## Indicator

The percentage of patients newly diagnosed with cancer, not via the urgent route, that started definitive treatment within (i.e. up to and including) 31 days of diagnosis (regardless of the referral route).

## Target:

98% - the target is monitored by individual Local Health Board (LHB).

## Rationale / Context

Cancer remains a top priority for Wales. Over the coming years, around 1 in 3 people will be diagnosed with cancer before age 75 and around 4 in 10 at some stage during their lifetime. Cancer is a common diagnosis and the incidence is increasing.

Early diagnosis and treatment increases someone's chance of survival and reduces likely harm to that person's health and their family's quality of life. Therefore, our aim in Wales is to treat patients as promptly as possible.

## **Data Source**

Aggregate Cancer Waiting Times Target Monitoring Form.

## **Definitions:**

## **Definitional Guidance:**

The Cancer Waiting Times Target Monitoring Form is an aggregate data collection. Whereas more complex methodologies could be applied to patient-level data sets, in this case, extensive definitional guidance has been provided to LHBs to enable them to determine the content of their aggregate returns. The central 'analysis' of these returns is then comprised of the straightforward selection of relevant counts for onward presentation.

The following data items and terms are relevant

#### Data Items:

n/a

#### Terms:

n/a

The definitions associated with all the data items and terms above can be accessed via the NHS Wales Data Dictionary - <a href="http://www.datadictionary.wales.nhs.uk">http://www.datadictionary.wales.nhs.uk</a>.

## **Detailed Specification**

Data relates to closed pathways.

Full guidance can be found in the following Health Circulars:

Definitions to support the cancer waiting times target <a href="http://www.wales.nhs.uk/sites3/docopen.cfm?orgid=362&id=85581">http://www.wales.nhs.uk/sites3/docopen.cfm?orgid=362&id=85581</a>

Monthly data collection of cancer waiting times to start of definitive treatment <a href="http://www.wales.nhs.uk/documents/WHC\_2005\_0271.pdf">http://www.wales.nhs.uk/documents/WHC\_2005\_0271.pdf</a>

AM 2014/01 Page 2 of 5

## Calculation:

## Numerator

The number of patients newly diagnosed with cancer, not via the urgent route, that started definitive treatment within (i.e. up to and including) 31 days of diagnosis.

#### Denominator

The total number of patients newly diagnosed with cancer, not via the urgent route, that started definitive treatment.

## **Reporting Frequency**

Aggregate returns are submitted monthly to Welsh Government by Welsh LHBs / Trusts by the last working day of each month.

Publication of performance also takes place on a monthly basis.

## **Areas for Future Development**

The following points reflect considerations raised by either the Analysis Methodologies Group or WISB in terms of aspects of the Analysis Method that require further investigation or development.

For a full breakdown of the issues considered, please refer to the formal WISB Outcome for this Analysis Method, which can be access via the Information Standards Assurance website:

http://howis.wales.nhs.uk/sites3/page.cfm?orgid=742&pid=52532

None applicable.

AM 2014/01 Page 3 of 5

# **Appendix A - Additional Information**

## **Cancer 31 Day Pro Forma**

#### MONTHLY CANCER TARGET MONITORING FORM - 'NON' URGENT SUSPECTED CANCER

Month ending:	Please select month	•						
Local Health Board Name:	Please select Local He	alth Board	Contact name and telephone number:					
	Total number of new cancer patients Numb		Number of newly diagnosed cancer patients <sup>(a)</sup> starting first definitive treatment this month, <b>NOT</b> within 31 days of diagnosis.				newly diagnosed	Number of newly diagnosed cancer
	diagnosed <sup>(9)</sup> this month, not included as urgent suspected cancer referrals.	cancer patients <sup>(a)</sup> starting first definitive treatment this month <b>AND</b> within 31 days of diagnosis		But between 39 and 48 days of diagnosis.		But after 62 days of diagnosis.	cancer patients <sup>(a)</sup> starting first definitive treatment this month.	patients <sup>(a)</sup> who have <b>NOT YET RECEIVED FIRST DEFINITIVE TREATMENT</b> at the end of this month <sup>(b)</sup> .
Tumour site:	Col. (1)	Col. (2)	Col. (3)	Col. (4)	Col. (5)	Col. (6)	Col. (7) = Total Cols. (2) to (6)	Col. (8)
Head and neck	55 (1)	5 S.I. (=)	- C - C - C - C - C - C - C - C - C - C	( · )	5511 (5)	5511 (5)	0	2 5 (4)
Upper Gastrointestinal							0	
Lower Gastrointestinal							0	
Lung							0	
Sarcoma							0	
Skin(c)							0	
Brain/CNS							0	
Breast							0	
Gynaecological							0	
Urological							0	
Haematological(d)							0	
Acute Leukaemia							0	
Children's cancer(e)				_			0	
Other(f)							0	

(2)	Not	included	20	urgont	cuenacted	cancor	roforro	de

(b) This should include all patients waiting, irrespective of when they were referred.

(c) Malignant Melanoma and squamous cell carcinoma only. Basal cell carcinomas to be excluded.

(d) Excluding acute leukaemia.

(e) All patients under 16 years of age at date of first treatment.

(f) All other cancers not mentioned above.

(g) With regards to SaFF waiting times reporting "date of diagnosis" = "date of decision to treat" = "date upon which the decision to treat was confirmed between a designated member of the MDT and the patient". See WHC(2005)027 for further information.

#DIV/0!

When complete, please email this spreadsheet to:

stats.health@wales.gsi.gov.uk

Enquiries: Alexandra Fitzpatrick on 029 2082 5016

## **Appendix B – SQL Code** (where applicable)

Important: The following code is intended for information purposes only. It will contain references to specific references (servers, data item descriptions etc.) that are applicable within the NHS Wales Informatics Service only and therefore will not be suitable for direct application to local (LHB) data.

n/a

AM 2014/01 Page 5 of 5